Two companies just cleared photon-counting CT in the same week. That doesn't happen by accident. GE HealthCare's Photonova Spectra, powered by a novel Deep Silicon detector, received FDA 510(k) clearance and headlined ACC.26 in Chicago. On the same day, MARS Bioimaging cleared a portable photon-counting CT for extremity imaging at the point of care. Across the aisle, Siemens Healthineers' Varian TrueBeam line cleared for low-dose radiation therapy in osteoarthritis, a non-oncology application for radiation tech that most people didn't see coming. And Medtronic quietly inked a distribution deal with Merit Medical to push a new back-pain ablation system into the market. It was a week that showed exactly where the next wave of MedTech R&D dollars went. Welcome to Issue #8 of The MedTech Minute.
Top Stories
Story 01
Photon-counting CT has been the most-anticipated technology shift in diagnostic imaging for years — and this week, it became a two-horse commercial race. (Source: BioSpace / GE HealthCare press release; Fierce Biotech)
GE HealthCare received FDA 510(k) clearance for its Photonova™ Spectra, a photon-counting CT system built on Deep Silicon detector technology. The system was showcased at ACC.26 in Chicago alongside a new collaboration with Gentuity for interventional cardiology imaging. Fierce Biotech reported the Photonova Spectra can capture up to 50 times more data than some of its premium CT predecessors.
GE joins Siemens Healthineers' NAEOTOM Alpha (cleared 2021) in the commercial PCCT market. Two systems, one market, two fundamentally different detector approaches. PCCT detectors count individual photons and measure their energy simultaneously — enabling multi-energy spectral data in a single scan, at no additional radiation dose. The imaging competition is now on.
Why This Matters
The Deep Silicon detector is a meaningful technological choice. Silicon handles high photon flux better than cadmium telluride (CdTe) detectors at clinical CT scan rates, it doesn't "pile up" as easily when photons arrive faster than the detector can count them individually. Whether silicon outperforms CdTe in spectral performance is an active debate, but the clearance signals GE is confident enough to take it to market. Founders building in AI-powered radiology: PCCT data is fundamentally different from conventional CT. Your models will need retraining or the accuracy gains you've engineered won't transfer. Plan accordingly.
FDA Clearance
Imaging
AI-Enabled
Story 02
Photon-counting CT is no longer confined to hospital imaging suites. On the same day as the GE HealthCare clearance, a portable PCCT cleared for point-of-care use — a fundamentally different access model for the technology. (Source: Imaging Technology News, March 24, 2026; DotMed)
MARS Bioimaging received FDA 510(k) clearance for its portable photon-counting CT scanner for upper extremity imaging. The device targets community hospitals, orthopedic clinics, and point-of-care settings that can't justify a conventional room-sized PCCT system. MARS has been building photon-counting CT for extremity applications since the early 2010s, with technology tracing back to CERN's Medipix detector collaboration.
The clinical case is strong. PCCT's spectral capability lets clinicians differentiate bone from cartilage from soft tissue in ways conventional CT can't match — useful for fracture characterization, implant planning, and osteoarthritis assessment. Two PCCT clearances in one week is a market signal: the era of spectral CT across multiple care settings has started.
FDA 510(k)
Imaging
Orthopedics
Story 03
Radiation therapy just stepped outside the oncology ward. Low-dose radiation for joint inflammation has been used off-label in European practice for decades — this week, it received formal FDA clearance in the U.S. for osteoarthritis. (Source: BusinessWire / Siemens Healthineers press release; ITN Online)
The Varian TrueBeam radiotherapy systems (TrueBeam, TrueBeam STx, VitalBeam, Edge) received FDA 510(k) clearance for low-dose radiation therapy (LDRT) in adults with medically refractory osteoarthritis. LDRT delivers very low doses — typically 0.5–1 Gy total, far below oncology doses — to the affected joint, reducing inflammation through anti-inflammatory cytokine modulation. Hospitals with existing TrueBeam linear accelerators can offer this indication with the same hardware already installed.
Osteoarthritis affects approximately 32.5 million U.S. adults. When NSAIDs and corticosteroids fail, treatment options have historically been limited to joint replacement or biologic injections. LDRT via installed hospital linac infrastructure is a meaningful new option. Episcopal Health Services in Far Rockaway, NY is already offering the indication. (Source: The Jewish Star) For radiology practices with TrueBeam systems, this expands the economic footprint of an already-installed asset.
FDA 510(k)
Radiation Therapy
Pain Management
Story 04
Basivertebral nerve ablation is becoming a two-player market. The indication targets chronic vertebrogenic low back pain — a form of pain that standard MRI findings often miss — and now has both the original pioneer and Medtronic's commercial network behind it. (Source: PRNewswire, March 24, 2026)
Medtronic and Merit Medical Systems announced a distribution agreement for the FDA-cleared ViaVerte™ system, a BVN ablation treatment for adults with chronic vertebrogenic low back pain. BVN ablation targets the sensory nerve innervating the vertebral endplate. Vertebrogenic pain accounts for an estimated 40–50% of chronic low back pain cases — a substantial addressable population.
Relievant Medsystems pioneered BVN ablation clearance with the Intracept system (acquired by Becton, Dickinson in 2023 for $850M). Medtronic distributing ViaVerte puts a second competitive system into the market under one of the most powerful sales forces in interventional spine. Chronic low back pain carries a $100B+ annual cost burden in the U.S. Medtronic entering distribution here is a market validation signal, not just a single product deal.
Distribution
FDA Cleared
Spine
Know someone in MedTech who needs this? Forward this issue to a colleague. Five minutes of signal, zero noise.
Market Movers
| Ticker | Company | Price | Wk Change |
|---|
| ISRG | Intuitive Surgical | $489.30 | ▼ 1.1% |
| SYK | Stryker | $361.40 | ▲ 2.1% |
| BDX | BD (Becton Dickinson) | $226.20 | ▼ 0.4% |
| JNJ | Johnson & Johnson | $164.80 | ▲ 1.1% |
| ABT | Abbott | $143.30 | ▲ 1.6% |
| ZBH | Zimmer Biomet | $111.20 | ▲ 0.6% |
| BSX | Boston Scientific | $108.00 | ▲ 1.9% |
| GEHC ★ | GE HealthCare | $94.20 | ▲ 3.8% |
| MDT | Medtronic | $87.30 | ▼ 1.5% |
| EW | Edwards Lifesciences | $76.50 | ▲ 0.9% |
★ Top Mover of the week (biggest % change). Sorted by stock price, highest to lowest. Data shown for illustrative purposes. Prices reflect approximate close, week of March 26, 2026.
Deep Dive
The Photon-Counting CT Revolution, Why Two Clearances in One Week Changes Diagnostic Imaging
Conventional CT has a fundamental limitation: each detector element measures integrated X-ray intensity, all the photons that hit it in a given time window, counted together as a single electrical signal. Photon-counting CT changes that equation at the detector level. Instead of integrated intensity, PCCT detectors count individual photons and simultaneously measure their energy. The practical result is a qualitatively different kind of data: multi-energy spectral information acquired in a single scan, at no extra radiation dose.
Three things worth unpacking from this week's dual clearances:
- Silicon vs. cadmium telluride is now a real commercial competition. Siemens Healthineers' NAEOTOM Alpha (cleared 2021) uses CdTe detectors. GE HealthCare's Photonova Spectra uses silicon. Both are direct-conversion photon-counting detectors, they convert X-ray photons directly to electrical signals without a scintillator layer. The difference is the semiconductor material. Silicon handles high photon-flux environments (like those in CT) with less pile-up at scan rates, but CdTe has better intrinsic spectral resolution at typical diagnostic photon energies. The clinical data to differentiate them in real-world radiology practice is still accumulating. Radiologists now have a choice.
- Portable PCCT changes the access equation entirely. MARS Bioimaging's clearance for a portable extremity PCCT is quietly the more disruptive of the two this week. Room-sized PCCT systems serve tertiary academic centers and large hospital networks, the same facilities that could already afford premium Siemens or GE conventional CT. A portable system opens an entirely different care setting: outpatient orthopedic clinics, urgent care centers, ambulatory surgery centers. Extremity PCCT won't replace whole-body systems, but it could reach orders of magnitude more patients for the specific use cases it serves.
- AI model retraining is the hidden challenge. Every AI algorithm trained on conventional CT data has a mismatch problem with PCCT data. The underlying image characteristics, noise structure, resolution, artifact profile, are different enough that models trained on conventional CT can't be assumed to generalize. Anyone building AI diagnostic tools for radiology needs to understand whether their target deployment environment will use conventional CT, PCCT, or a mix. The answer should be driving training data strategy now, not after clearance.
The bottom line: The photon-counting CT market went from one cleared platform to three in this week alone (NAEOTOM Alpha, Photonova Spectra, MARS portable). The clinical evidence base for PCCT advantages in vascular imaging, oncology staging, and material decomposition is growing, but the field is still early enough that radiologists are still learning what these systems can do. The next 18 months will determine whether PCCT becomes the standard for premium CT or remains a specialized tool. The commercial competition will accelerate the answer.
Industry Shifts
Shift 01
Peer-reviewed publication is how medical devices earn credibility at hospital value analysis committees. For endovascular robotics — a competitive and relatively young market — published pivotal data changes the procurement conversation. (Source: GlobeNewswire, March 24, 2026)
Microbot Medical published ACCESS PVI pivotal study results for its LIBERTY® Endovascular Robotic System in a peer-reviewed medical journal. LIBERTY targets peripheral vascular interventions (PVI) for peripheral artery disease. In a competitive space that includes Siemens/Corindus and Philips, published clinical backing from a pivotal study is a prerequisite for serious commercial traction. Microbot now has it.
Endovascular
Clinical Data
Vascular
Shift 02
Large-cap MedTech stocks face a consistent dynamic after portfolio spin-outs: removing one headwind exposes the next one. Medtronic's Q1 2026 trading illustrates the pattern. (Source: Ad Hoc News, March 25, 2026)
Medtronic shares declined 1.5% this week as analysts assessed mixed quarterly signals — competitive headwinds in pacemakers and ongoing cardiovascular device scrutiny. The ViaVerte distribution agreement (Story 04 above) shows the commercial machine is still active. But the stock performance reflects what public analyst commentary confirms: investors want organic growth acceleration, not just distribution deals, before rerating the name higher. The MiniMed spin-out removed the diabetes overhang. Cardiovascular execution is now the story in public analyst coverage.
Market Watch
Cardiology
Investor Pressure
AI in MedTech
What Photon-Counting CT Actually Means for AI in Diagnostic Imaging, And Why Most Builders Aren't Ready
Let's be direct about something: most AI imaging companies don't know what photon-counting CT data looks like in production. They've trained on retrospective DICOM archives from conventional CT systems, and those archives are enormous. Models trained on tens of thousands of conventional CT scans for lung nodule detection, liver segmentation, or vascular assessment will not automatically perform the same way on PCCT data. The image characteristics are different in ways that matter: finer spatial resolution, different noise texture, spectral channels that don't exist in conventional CT.
The clinical promise of AI + PCCT is significant. Multi-energy spectral information means you can differentiate iodine from calcium from uric acid (gout crystal deposition) in a single scan, without the radiation overhead of separate acquisitions. An AI model trained on PCCT spectral data could automate material decomposition that currently requires a radiologist manually adjusting energy levels. Coronary artery plaque characterization, differentiating lipid-rich plaque (higher MI risk) from calcified plaque, becomes more tractable with PCCT's spectral resolution. These are not incremental improvements. They're genuinely new diagnostic capabilities.
What builders need to do now: first, identify whether your target customers are early PCCT adopters or still on conventional CT, and plan your commercial roadmap accordingly. Second, if you're in a clinical area where PCCT changes the diagnostic picture (vascular imaging, oncology staging, musculoskeletal), start now on acquiring PCCT training data through academic partnerships before the commercial PCCT install base outpaces your data collection. Third, watch how GE and Siemens market the AI capabilities bundled with their PCCT systems, they are building the frame of what "AI + PCCT" means before independent AI developers have a chance to define it. Getting there first with validated evidence is still possible. But the window is narrowing.
Fun Fact & Trivia
Fun Fact
A conventional CT scanner generates roughly 800 to 1,000 milliamps of X-ray tube current during a chest scan, producing a flood of hundreds of millions of photons per second. A photon-counting CT detector must resolve individual photons within that flood and simultaneously measure each one's energy. To prevent "photon pile-up" (where two photons arrive faster than the detector can separate them and get miscounted as one), modern PCCT detectors operate at count rates exceeding 10 million photons per second per square millimeter. The silicon detectors in GE's Photonova Spectra were engineered to handle this at full clinical CT flux rates, a materials science challenge that's been decades in the making. The technology originated, in part, from high-energy physics particle detectors developed at CERN.
MedTech Trivia
Medtronic's new ViaVerte distribution deal targets basivertebral nerve ablation for chronic back pain. Which company pioneered FDA clearance for basivertebral nerve ablation, and what was their pivotal device called?
👇 Scroll to the footer for the answer
MedTech Word Search
🧩 Find the Hidden MedTech Terms, Click to Highlight
PHOTON
IMAGING
CARDIAC
MEDTECH
SILICON
VARIAN
Words hidden horizontally (→) and vertically (↓). Click letters to mark your finds.
Quick Question
Radiologists and AI builders, are you already planning for photon-counting CT in your pipeline? Retrain on PCCT data, wait for conventional CT to dominate longer, or ignore PCCT for now? I want to know what practitioners and builders are actually doing. Hit reply, I read every response.
Sponsor
